Advances in Hematology and Oncology Research最新文献

{"title":"Effect of Storage on Osmotic Fragility in CPDA-1 Stored Blood in Sokoto, Northwestern Nigeria","authors":"","doi":"10.33140/ahor.01.01.02","DOIUrl":"https://doi.org/10.33140/ahor.01.01.02","url":null,"abstract":"The aim of this study was to investigate the effects of storage on the in vitro osmotic fragility of erythrocytes of humans in a single unit of whole blood. Blood was collected by venepunture from a healthy adult male (70-75 kg) into CPDA-1(450ml) blood bag containing citrate phosphate dextrose as anticoagulant (63ml) and stored in a blood bank maintained at 4°c ± 2°c. The osmotic fragility of the erythrocytes was determined by measuring the release of haemoglobin from blood added to tubes containing serially diluted phosphate buffered saline (pH 7.4). The Blood samples were analyzed on day 1 to day 35 after collection (5 weeks). Increased erythrocyte osmotic fragility was observed at week 3 (p=0.010). The initial haemolysis (>5%) occurred between 0.50% and 0.55% PBS. The mean corpuscular fragility was between 0.35 and 0.45% PBS. Maximum haemolysis occurred in 0.35% PBS. Osmotic fragility was significantly affected by storage (p<0.05). In conclusion, this research showed that there is an increase in the osmotic fragility as donor blood is stored and that the effect is more pronounced from week 3. There is need to maintain the cold chain management of stored donor blood to ensure that the aim of red cell transfusion which is to manage anaemia and increase the oxygen carrying capacity is not compromised.","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"108 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124811572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron in the Promotion and Initiation of Cancer How Free Iron Accelerates Predisposing Insulin Resistance","authors":"","doi":"10.33140/ahor.01.01.01","DOIUrl":"https://doi.org/10.33140/ahor.01.01.01","url":null,"abstract":"Iron is physiologically essential to life, but biochemically it is harmful because of its evident -but unappreciated- oxidative and inflammatory tissue power when it accumulates, is dosed in excess, or is free; and that because, after entering the body, unlike any other metal, its elimination is almost non-existent in man; thus, metal is a powerful promoter of chronic degenerative diseases, from diabetes, neurodegeneration to cancer, through extensive coronary and cardio-cerebrovascular disease; modifying its clinical expressivity and accelerating its severity. Iron is a powerful oxidizing and inflammatory agent, and its accumulation causes and promotes the proliferation of cancer cells in particular, both in animals and in humans. Free and accumulated iron triggers a powerful uncontrolled Cell Proliferation, permanently feeding the survival of the neoplastic cell. After more than 50 years of experimental and preclinical studies, it is clearly demonstrating the carcinogenicity of iron; and this is also proven in humans, from breast cancer and endometrium, in women, to cancer of the colon-rectum, prostate, and pancreas in men. In Western men and women, the reductions in iron deposits have an important anti-tumor and preventive effect for the development of cancer or diabetes, two entities biologically interrelated by the states of Resistance to Insulin, an inflammatory state that favors the development of malignant neoplasms, and can accelerate its aggressiveness. It is the chronic excess of insulin or its Tissue Resistance, the biological event and the clinical syndrome that increases the cancerous power of excess iron, both silent epidemics in modern man. Moderate increases in body iron levels increase the risk of acquiring cancer, and raise the level of their mortality. And its deficiency or chelation in vivo decreases the Tumor growth (Wang F, Elliott RL, Head JF: Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma Anticancer Res. 1999 Jan-Feb; 19 (1A): 445-50). If excess iron mediates and increases the risk of cancer associated with Insulin resistance, any subject with this syndrome can minimize any associated health risks (and their increased risk of cancer), avoiding iron-rich diets and donating blood with regularity; Iron is the metal that causes “exponential” and punctual mutations and fusion of genes through chromosomal translocations, constituting the greatest risk factor for human carcinogenesis. Iron is physiologically essential for life but biochemically dangerous. Chronic accumulation of iron causes pantropic organ damage and excess body iron play an important role in carcinogenesis, coronary artery disease, neurodegenerative disease, stroke and inflammatory disorders. Iron is very slowly excreted from humans once it is absorbed into the body. The significance of iron excess has been markedly underestimated, despite the fact that iron overloading disorders are as common place in the","PeriodicalId":134553,"journal":{"name":"Advances in Hematology and Oncology Research","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114160423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}